retatrutide obesity treatment Medscape | Retatrutide, Eli Lilly's first-in-class triple hormone receptor agonist, delivered meaningful weight loss at 80 weeks in all doses in the Retatrutide Severe Obesity Trial Shows

Table of Contents: How does semaglutide GLP-1 work for weight loss

Soon came tirzepatideMounjaro, then Zepbound

Most patients report little to no discomfort, and the injection is required only once per week

This type of diabetes is known as hepatogenous diabetes (HD).6 DM and Cirrhosis Retrospective studies have shown that DM is associated with an increased risk of hepatic complications and death in patients with liver cirrhosis.79 DM is associated with hepatic encephalopathy,10 portal hypertension and bleeding from esophageal varices in decompensated patients.11 In a cohort of individuals with liver infection by HBV, those who developed de novo DM had higher risk of developing cirrhosis and hepatic complications.12 In patients with chronic hepatitis C, DM was an independent predictor of hepatic complications such as ascites, spontaneous bacterial peritonitis, renal dysfunction and hepatocellular cancer.13 DM also has a negative impact on survival of cirrhotic patients